Topic: drug-coated balloon
Medtronic’s drug-coated balloon for collapsing dialysis access vessels has met its primary endpoints in its first large study.
Concept Medical received an FDA breakthrough designation for its balloon designed to open a collapsed access vessel used during dialysis.
Hot on the heels of an international distribution deal with Terumo, Orchestra BioMed has secured $34 million in new funding for its devices.
Terumo will help Orchestra BioMed develop its sirolimus-eluting balloon in both coronary and peripheral cardiovascular interventions.
The drug-eluting balloon opens up the coronary arteries after they’ve reclogged without using a traditional drug coating.
Medtronic’s final, five-year study data showed the durability of its drug-coated angioplasty balloon in peripheral artery disease.
Abbott is paying $25 million upfront and committing to up to $67 million in development milestones to add the device to its vascular disease pipeline.
C.R. Bard scored FDA approval for its Lutonix drug-coated balloon to treat a complication of end-stage renal disease.
VentureMed Group raised $15 million to support R&D, clinical trials and expand the sales team for its PAD treatment catheter.
Medtronic won FDA approval for its drug-coated balloon to treat in-stent restenosis in patients with peripheral artery disease. The news is a feather in the company’s cap as it attempts to broaden its lead in the drug-coated balloon market.